Gene · 152
ADRA2C: adrenoceptor alpha 2C
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADRA2C: adrenoceptor alpha 2C. Genes, record 152. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/152
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P18825 | Alpha-2C adrenergic receptor | 462 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents24
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36847 | P18825 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 335 | P18825 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 335 | P18825 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3469 | P18825 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3469 | P18825 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 198 | P18825 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 106440 | P18825 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 305 | P18825 | Espacenet |
| US 10772934 B2 | 2020-09-15 | 1229 | P18825 | Espacenet |
| US 10302646 B2 | 2019-05-28 | 153 | P18825 | Espacenet |
1 to 10 of 24
See all 24 patentsDrugs67
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALSEROXYLON | CHEMBL1201454 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| APRACLONIDINE | CHEMBL647 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| APRACLONIDINE HYDROCHLORIDE | CHEMBL1200379 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| AVIPTADIL | CHEMBL1981592 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| BRIMONIDINE | CHEMBL844 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| BRIMONIDINE TARTRATE | CHEMBL1200389 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| CELIPROLOL | CHEMBL27810 | Adrenergic receptor alpha-2 antagonist | ANTAGONIST | ChEMBL |
| CLONIDINE | CHEMBL134 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| CLONIDINE HYDROCHLORIDE | CHEMBL1705 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
| DEXMEDETOMIDINE | CHEMBL778 | Adrenergic receptor alpha-2 agonist | AGONIST | ChEMBL |
1 to 10 of 67
See all 67 drugsTrials1,038
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07603596 | DEXMEDETOMIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT07585201 | DEXMEDETOMIDINE | ClinicalTrials.gov | ||
| NCT07573969 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07572656 | LABETALOL | ClinicalTrials.gov | ||
| NCT07569536 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07564531 | DEXMEDETOMIDINE | ClinicalTrials.gov | ||
| NCT07557680 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07542990 | DEXMEDETOMIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07537894 | DEXMEDETOMIDINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07532733 | DEXMEDETOMIDINE | ClinicalTrials.gov |
1 to 10 of 1,038
See all 1,038 trialsNIH grants730
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADRA2C papers | Newest fiscal year |
|---|---|---|---|
| R35GM136397 | GPCR anterograde trafficking | 4 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 4 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P30DK020579 | Diabetes Research Center | 2 | 2025 |
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 2 | 2025 |
| ZIADA000606 | Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptor | 2 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 1 | 2025 |
| P01CA108671 | Myeloproliferative Neoplasms-Research Consortium | 1 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 1 | 2025 |
| P30AR073752 | Washington University Rheumatic Diseases Research Resource-based Center | 1 | 2025 |
1 to 10 of 730Source NIH's project files
See all 730 nih grantsPapers944
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| JP-1302 inhibits RNA polymerase I transcription and induces nucleolar stress in cancer cell lines. | Cell Death Discov | 2026 | 42816485 | PubTator, text mining | PubMed |
| Endometriosis pain: genes linked to inflammation distinguish symptomatic from asymptomatic disease. | Mol Hum Reprod | 2026 | 42720599 | PubTator, text mining | PubMed |
| Novel Substituted Heterocyclic Carboxamindes as α2C-ARs Antagonists. | ACS Med Chem Lett | 2026 | 42445021 | PubTator, text mining | PubMed |
| An Exploratory Study of High-Concentration Trace Amine Effects and Adrenoceptor Expression Patterns in SH-SY5Y Cells and Neuroblastoma. | Int J Mol Sci | 2026 | 42278562 | PubTator, text mining | PubMed |
| Leveraging Signal Detection and Mendelian Randomization in Spontaneous Reporting for Post-Marketing Surveillance of Drug- Induced Amnesia. | Curr Med Chem | 2026 | 41941166 | PubTator, text mining | PubMed |
| Neuroimmunological Mechanisms of Xiao-Yao-San Against Chronic Stress-Induced Colorectal Cancer: A Bioinformatics and Single-Cell Sequencing Study. | Cancer Manag Res | 2026 | 41798904 | PubTator, text mining | PubMed |
| ROCK signaling at the crossroads of redox stress, mitochondrial dynamics, and metabolic disease. | Redox Biol | 2026 | 41791289 | PubTator, text mining | PubMed |
| Integrative network toxicology and experimental evidence reveal mechanisms underlying diethyl phthalate-induced initiation and progression of endometrial cancer. | Sci Rep | 2026 | 41667778 | PubTator, text mining | PubMed |
| Ribosome biogenesis is increased in hepatocellular carcinoma and represents a potential therapeutic target. | NAR Cancer | 2026 | 41551405 | PubTator, text mining | PubMed |
| Ribosome occupancy and miRNA-mediated silencing of upregulated genes in attention deficit hyperactivity disorder. | Comput Biol Chem | 2026 | 41391262 | PubTator, text mining | PubMed |
1 to 10 of 944
See all 944 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/152
GET https://conductscience.org/api/genes/v1/152/patents?page=2